Telitacicept as an alternative to non-steroidal immunosuppressive therapies in the treatment of myasthenia gravis: a study on clinical efficacy and steroid-sparing effect

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: March 24, 2025

Introduction Myasthenia Gravis (MG) is an autoimmune disorder characterized by impaired neuromuscular junction (NMJ) transmission. Current treatments for MG include steroids and nonsteroidal immunosuppressive therapies (NSISTs). However, approximately 20% of patients show a poor response to these therapies, which are often associated with significant side effects. Telitacicept, novel recombinant fusion protein targeting the BAFF/APRIL pathway, has shown promise in treating diseases, including MG. Methods This retrospective study compared efficacy telitacicept monotherapy (10 patients) NSISTs (16 sequential therapy (6 managing at The First Affiliated Hospital Wenzhou Medical University (July 2020-November 2024). primary endpoint was time achieve minimal symptom expression (MSE), secondary change mean daily prednisone dosage from baseline month 4. Results Among telitacicept-treated patients, 80% achieved MSE within 4 months, reduction dose (from 45.00 mg 6.25 mg, P < 0.001). In contrast, only 12.5% group MSE, no ( = 0.091). (efgartigimod followed telitacicept) maintained stable disease conditions. Conclusion Telitacicept effective inducing rapidly offers steroid-sparing effect, making it promising alternative traditional fewer effects patients.

Language: Английский

---

Myasthenia Gravis, Immunology of

Elsevier eBooks, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

---